Nutlin-3 induces HO-1 expression by activating JNK in a transcription-independent manner of p53

International Journal of Oncology

Volumn 44, Issue 3, 2014, Pages 761-768

  Choe, Yun Jeong ^a   Lee, Sun Young ^a   Ko, Kyung Won ^a   Shin, Seok Joon ^a   Kim, Ho Shik ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

c jun N terminal kinase; Heme oxygenase 1; Murine double minute 2 protein; Nutlin 3; Tumor suppressor protein p53

Indexed keywords

HO 1 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NUTLIN 3; PROTEIN; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; HUMAN; HUMAN CELL; MITOCHONDRION; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HEME OXYGENASE-1; HUMANS; IMIDAZOLES; MAP KINASE KINASE 4; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84896696089     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2227     Document Type: Article

References (36)

1. Menendez D, Inga A and Resnick MA: The expanding universe of p53 targets. Nat Rev Cancer 9: 724-737, 2009.
2. Riley T, Sontag E, Chen P and Levine A: Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9: 402-412, 2008.
3. Gartel AL and Tyner AL: The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 1: 639-649, 2002.
4. Chan TA, Hermeking H, Lengauer C, Kinzler KW and Vogelstein B: 14-3-3s is required to prevent mitotic catastrophe after DNA damage. Nature 401: 616-620, 1999.
5. Cohen HY, Lavu S, Bitterman KJ, et al: Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell 13: 627-638, 2004.
6. Wu WS, Heinrichs S, Xu D, et al: Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma. Cell 123: 641-653, 2005.
7. Janssens S, Tinel A, Lippens S and Tschopp J: PIDD mediates NF-kappaB activation in response to DNA damage. Cell 123: 1079-1092, 2005.
8. Fang L, Li G, Liu G, Lee SW and Aaronson SA: p53 induction of heparin-binding EGF-like growth factor counteracts p53 growth suppression through activation of MAPK and PI3K/Akt signaling cascades. EMBO J 20: 1931-1939, 2001.
9. Ongusaha PP, Kim JI, Fang L, et al: p53 induction and activation of DDR1 kinase counteract p53-mediated apoptosis and influence p53 regulation through a positive feedback loop. EMBO J 22: 1289-1301, 2003.
10. Wade M, Li YC and Wahl GM: MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 13: 83-96, 2013.
11. Vassilev LT, Vu BT, Graves B, et al: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848, 2004.
12. Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W and Andreeff M: Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription- dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 108: 993-1000, 2006.
13. Vassilev LT: MDM2 inhibitors for cancer therapy. Trends Mol Med 13: 23-31, 2007.
14. Tovar C, Rosinski J, Filipovic Z, et al: Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 103: 1888-1893, 2006.
15. Enge M, Bao W, Hedstrom E, Jackson SP, Moumen A and Selivanova G: MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell 15: 171-183, 2009.
16. Rinaldo C, Prodosmo A, Siepi F, et al: HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA. Cancer Res 69: 6241-6248, 2009.
17. Lee SY, Shin SJ and Kim HS: ERK1/2 activation mediated by the nutlin3-induced mitochondrial translocation of p53. Int J Oncol 42: 1027-1035, 2013.
18. Ryter SW, Alam J and Choi AM: Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev 86: 583-650, 2006.
19. Yang JD, Nakamura I and Roberts LR: The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol 21: 35-43, 2011.
20. Was H, Dulak J and Jozkowicz A: Heme oxygenase-1 in tumor biology and therapy. Curr Drug Targets 11: 1551-1570, 2010.
21. Berberat PO, Dambrauskas Z, Gulbinas A, et al: Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. Clin Cancer Res 11: 3790-3798, 2005.
22. Rushworth SA and MacEwan DJ: HO-1 underlies resistance of AML cells to TNF-induced apoptosis. Blood 111: 3793-3801, 2008.
23. Guan J, Wu X, Arons E and Christou H: The p38 mitogen-activated protein kinase pathway is involved in the regulation of heme oxygenase-1 by acidic extracellular pH in aortic smooth muscle cells. J Cell Biochem 105: 1298-1306, 2008.
24. Alam J and Cook JL: How many transcription factors does it take to turn on the heme oxygenase-1 gene? Am J Respir Cell Mol Biol 36: 166-174, 2007.
25. Nam SY and Sabapathy K: p53 promotes cellular survival in a context-dependent manner by directly inducing the expression of haeme-oxygenase-1. Oncogene 30: 4476-4486, 2011.
26. Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108, 2008.
27. Jang JY, Kim MK, Jeon YK, Joung YK, Park KD and Kim CW: Adenovirus adenine nucleotide translocator-2 shRNA effectively induces apoptosis and enhances chemosensitivity by the down-regulation of ABCG2 in breast cancer stem-like cells. Exp Mol Med 44: 251-259, 2012.
28. Lau LM, Nugent JK, Zhao X and Irwin MS: HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene 27: 997-1003, 2008.
29. Zhao Y, Chaiswing L, Velez JM, et al: p53 translocation to mitochondria precedes its nuclear translocation and targets mitochondrial oxidative defense protein-manganese superoxide dismutase. Cancer Res 65: 3745-3750, 2005.
30. Mihara M, Erster S, Zaika A, et al: p53 has a direct apoptogenic role at the mitochondria. Mol Cell 11: 577-590, 2003.
31. Palacios G, Crawford HC, Vaseva A and Moll UM: Mitochondrially targeted wild-type p53 induces apoptosis in a solid human tumor xenograft model. Cell Cycle 7: 2584-2590, 2008.
32. Leu JI, Dumont P, Hafey M, Murphy ME and George DL: Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 6: 443-450, 2004.
33. Vaseva AV, Marchenko ND, Ji K, Tsirka SE, Holzmann S and Moll UM: p53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell 149: 1536-1548, 2012.
34. Vaseva AV, Marchenko ND and Moll UM: The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells. Cell Cycle 8: 1711-1719, 2009.
35. Essmann F, Pohlmann S, Gillissen B, Daniel PT, Schulze-Osthoff K and Janicke RU: Irradiation-induced translocation of p53 to mitochondria in the absence of apoptosis. J Biol Chem 280: 37169-37177, 2005.
36. Moreno CS, Matyunina L, Dickerson EB, et al: Evidence that p53-mediated cell-cycle-arrest inhibits chemotherapeutic treatment of ovarian carcinomas. PLoS One 2: e441, 2007.